UK: Gastroenterology AI-Based Dietary Regime Alleviates Widespread Gastrointestinal Disorder
Following recent clinical trial, biotech firm Enbiosis announces a breakthrough in the treatment of irritable bowel syndrome, which affects one in every ten people.
London/UK — The biotech venture Enbiosis has achieved a significant breakthrough in the treatment of irritable bowel syndrome (IBS), company officials announced. “Seventy-eight percent of the IBS patients who took part in our study saw their symptoms improve dramatically,” Professor Dr. Tarkan Karakan, a gastroenterology specialist who helped conduct the study, says. “We believe this achievement represents a significant step towards demonstrating the efficacy of personalized medical solutions.”
A relative newcomer to the biotech world, the company launched its operations in 2019. Since then, it has sought ways of using human gut bacteria to treat a range of common health disorders, including obesity, diabetes, eczema and IBS. It has also developed a system of personalized nutritional programs based on the findings of microbiome tests, which analyse human gut bacteria. The company uses artificial intelligence technology to find solutions for the prevention and the early diagnosis and treatment of diseases.
For the treatment of IBS, the researchers examined intestinal flora of IBS sufferers before prescribing dietary regimes based on the findings. According to Dr. Karakan this novel approach to IBS treatment “is the first time for microbiome modulation to be used to alleviate symptoms of gastrointestinal disorders.”
According to Özkan Ufuk Nalbantoğlu, Enbiosis chief technology officer, 78 % of those who followed microbiome-based diets saw their symptoms ease — from severe to moderate — by the end of the study. “We hope to soon present these excellent findings before an international medical forum,” he says.